Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Real-World Effectiveness of SGLT2 Inhibitors Across Heart Failure Phenotypes: A Meta-Analysis.

Journal of diabetes research - 1 Jan 2026

A E Mohammed Elmujtba, Ahmed Abdelkareem A

Abstract excerpt

BACKGROUND: Sodium-glucose co-transporter-2 (SGLT2) inhibitors have demonstrated significant benefits in heart failure (HF) patients in randomised controlled trials (RCTs). However, real-world evidence (RWE) is crucial to confirm their efficacy in broader, unselected patient populations. This meta-analysis is aimed at synthesising real-world data on SGLT2 inhibitors in HF across various ejection fraction...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Heart Failure
Share to Hospitalization
Share to Observational Studies as Topic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Phenotype

Share to Stroke Volume

Share to Treatment Outcome

Source

Open in PubMed Open full text

Identifiers

PMID: 42126925
DOI: 10.1155/jdr/6584068
PMCID: PMC13170705

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Real-World Effectiveness of SGLT2 Inhibitors Across Heart Failure Phenotypes: A Meta-Analysis.PMID 42126925Read ↗

Effect of SGLT-2 Inhibitors on Cardiovascular Outcomes Among Patients With Heart Failure and Type 2 Diabetes Mellitus: A Systemic Review and Meta-Analysis of Randomized Controlled TrialsSemantic proximity Read ↗

Efficacy and safety of SGLT2 inhibitors in the treatment of heart failure-May raise creatinine levels in patients: A meta-analysisSemantic proximity Read ↗

SGLT2i, ARNi and Diuretic Use in Patients with Heart Failure Among the Preserved and Reduced Ejection Fraction: A Retrospective Observational StudySemantic proximity Read ↗

Comparative Effectiveness of Second-line Antihyperglycemic Agents for Cardiovascular Outcomes: A Large-scale, Multinational, Federated Analysis of the LEGEND-T2DM StudySemantic proximity Read ↗

Left Ventricular Remodeling Response to SGLT2 inhibitors in Heart Failure: An Updated Meta-analysis of Randomized Controlled StudiesSemantic proximity Read ↗

Cardiovascular drugs approved for heart failure with reduced ejection fraction and/or post-myocardial infarction exert consistent effects in both populations: A meta-analysis and meta-regression of randomized controlled trialsSemantic proximity Read ↗

Patient-level comparison of heart failure patients in clinical phenotype and prognosis from China and Sweden.Semantic proximity Read ↗

Comparative cardiovascular effectiveness of glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter-2 inhibitors in atherosclerotic cardiovascular disease phenotypes: a systematic review and meta-analysis.Semantic proximity Read ↗

Harnessing the Synergy of SGLT2 Inhibitors and Continuous Ketone Monitoring (CKM) in Managing Heart Failure Among Patients with Type 1 DiabetesSemantic proximity Read ↗

Underuse of Guideline-Directed Medical Therapy Across Heart Failure Phenotypes in Older Outpatients: A Multicenter Cross-Sectional Study in Vietnam.Semantic proximity Read ↗

Genetic Variation in Sodium-glucose Cotransporter 2 and Heart Failure.Semantic proximity Read ↗

Heterogeneous Treatment Effects in HFpEF: Distinguishing Drug-Specific Response from Prognostic Phenotypes Across Randomized TrialsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.